Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Megan Benedict

Physician Assistant Fort Carson, CO Physician Assistant

NPI 1104439181 CMS profile 10467405

1650 Cochrane Cir Unit Meddac, Fort Carson, CO 80913

Open in the dashboard

General payments

$2,374

148 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Megan Benedict of Fort Carson, CO is reported in the CMS Open Payments database as having received $2,374 across 148 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $358 21
2022 General $937 59
2021 General $1,080 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Benedict
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Megan Benedict were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Megan Benedict Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,080 $132 $37–$438 $132
2022 $937 $155 $48–$522 $149
2023 $358 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AbbVie, Inc. $569 33 payments
  2. Novo Nordisk Inc $302 28 payments
  3. Lilly USA, LLC $250 17 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $231 9 payments
  5. AstraZeneca Pharmaceuticals LP $229 16 payments
  6. Teva Pharmaceuticals USA, Inc. $99 4 payments
  7. GlaxoSmithKline, LLC. $92 6 payments
  8. Amgen Inc. $90 5 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $63 3 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $54 4 payments
  11. Other $395 23 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,374 148 payments
Products named General payments · program years 2021–2023
  1. VRAYLAR $249 13 payments
  2. Ozempic $222 23 payments
  3. GLASSIA $214 8 payments
  4. QULIPTA $201 13 payments
  5. RYBELSUS $189 18 payments
  6. EMGALITY $152 9 payments
  7. FARXIGA $148 10 payments
  8. JARDIANCE $120 8 payments
  9. UBRELVY $118 7 payments
  10. REYVOW $83 5 payments
  11. Other $1,198 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

148 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record